Key Metrics of Sun Pharma Laboratories Limited
About Sun Pharma Laboratories Limited
Sectors
Company details
- Registered office
- Sun Pharma Advanced Research Centre (sparc), Tandalja,, Vadodara, In-gj, 390012
Operational Areas of Sun Pharma Laboratories Limited
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 13 Oct 2026 | ICRA | Reaffirmed | — | A1+ | — | ₹150 Cr | View |
| 05 May 2026 | ICRA | Other | — | A1+ | — | ₹150 Cr | View |
Credit strengths (ICRA, Oct 2026)
+ Integrated presence across value chain
SPIL has an integrated presence across the value chain.
Credit challenges
− Base US pharmaceutical generics business remains competitive; regular product introductions expected to mitigate risk to an extent
SPIL’s base US generics business remains impacted by continued price erosion.
− Ongoing litigations, regulatory non-compliances at some manufacturing facilities as well as exposure to regulatory risks
Like its peers, SPIL remains exposed to the risk of scrutiny by regulatory agencies such as the USFDA.
Could lead to a downgrade
Pressure on the ratings could emerge from any significant weakening in the company’s profitability, adversely impacting its credit profile. Delays in resolving existing regulatory non-compliances or any other regulatory non- compliance relating to SPIL’s products and/or manufacturing facilities, impacting product launches, revenues and profitability, would also be negative rating triggers. Any adverse outcome of the ongoing litigations/lawsuits would remain event risks, and the impact of such events on the company’s business, credit profile and
Agency-reported financials (ICRA, 13 Oct 2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
| Operating income | ₹52,793 Cr | ₹59,720 Cr |
| PAT | ₹10,980 Cr | ₹11,565 Cr |
| OPBDIT/OI | 29.0% | 29.8% |
| PAT/OI | 20.8% | 19.4% |
| Total outside liabilities/Tangible net worth (times) | 0.20× | 0.20× |
| Total debt/OPBDIT (times) | 0.20× | 0.30× |
| Interest coverage (times) | 66.30× | 52.50× |
| Revenue growth (YoY) | — | 13.1% |
| EBITDA (margin × income) | ₹15,310 Cr | ₹17,796 Cr |
| Implied total debt (debt/EBITDA × EBITDA) | ₹3,062 Cr | ₹5,339 Cr |
| Implied interest cost (EBITDA ÷ coverage) | ₹231 Cr | ₹339 Cr |
Borrowings & rated debt
Rated limits over time
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Short-term, fund-based non-fund based limits | Non-fund based limits | ₹150 Cr | ₹150 Cr | 0.0% | A1+ | Reaffirmed | ICRA |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 61% |
| Information on file | 33% · missing: Annual results history (3+ years), Liquidity position, Debt obligations and repayment schedule, Capex / investment plans, Auditor details, Shareholding pattern |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 45% chance the next rating action is stable or better
- Interest coverage 52.5×
Rated limits by facility
Timeline
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Sun Pharma Laboratories Limited
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Dr. Reddy's Laboratories |
Part of Dr. Reddy's Laboratories. | drreddys.com | 1984 | India |
 Aurobindo Pharma |
Part of Aurobindo Pharma. | aurobindo.com | 1986 | Hyderabad, India |
 Cipla |
Part of Cipla. | cipla.com | 1935 | Mumbai, India |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lupin.com | 1968 | India | |
 Glenmark Pharmaceuticals |
Part of Glenmark Pharmaceuticals. | glenmarkpharma.com | 1977 | Mumbai, India |
| Part of Biocon. | biocon.com | 1978 | Bangalore, India | |
 Alkem Laboratories Limited |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | alkemlabs.com | 1973 | Mumbai, Maharashtra, India |
 Torrent Pharmaceuticals |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | torrentpharma.com | 1959 | Ahmedabad, India |
| Aster DM Quality Care Limited | Discovered Companies · Other Industries | — | — | Hyderabad, Telangana, India |
 Thomas Cook India |
Part of Thomas Cook Group. | thomascook.in | 1978 | Mumbai, India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.